At least a million people, mainly African children under 5 years old, still die yearly from malaria, and the burden of disease and death has increased. Plasmodium falciparum apical membrane antigen 1 (PfAMA1) is one of the most promising blood-stage malarial vaccine candidates. However, the allelic polymorphism observed in this protein is a potential stumbling block for vaccine development. To overcome the polymorphismand strain-specific growth inhibition in vitro, we previously showed in a rabbit model that vaccination with a mixture of two allelic forms of PfAMA1 induced parasite growth-inhibitory antisera against both strains of P. falciparum parasites in vitro. In the present study, we have established that, in contrast to a single-allele protein, the antigen mixture elicits primarily antibodies recognizing antigenic determinants common to the two antigens, as judged by an antigen reversal growth inhibition assay (GIA). We also show that a similar reactivity pattern occurs after immunization of mice. By contrast, sera from rhesus monkeys do not distinguish the two alleles when tested by an enzyme-linked immunosorbent assay or by GIA, regardless of whether the immunogen is a single AMA1 protein or the mixture. This is the first report that a malarial vaccine candidate induced different specificities of functional antibodies depending on the animal species immunized. These observations, as well as data available on human immune responses in areas of endemicity, suggest that polymorphism in the AMA1 protein may not be as formidable a problem for vaccine development as anticipated from studies with rabbits and mice.The malarial parasite remains a scourge on human civilization, and recent data suggest that previous estimates of malaria morbidity and mortality may have significantly underestimated the worldwide burden of this disease. Snow and colleagues estimate that there may be 300 to 500 million clinical cases of malaria annually, a rate approximately twice as high as previous estimates (42). To compound the human toll of this disease, recent macroeconomic analysis by the WHO Commission on Macroeconomics and Health has found that malaria reduces economic growth in sub-Saharan Africa by over 1% per year, with major long-term consequences for the gross national products of the afflicted countries (41). As the burden of disease and death due directly and indirectly to malaria has increased, the need for an effective vaccine has also assumed greater importance (4, 29).Of the major vaccine candidates directed against bloodstage malaria parasites which are responsible for the pathology associated with this disease, Plasmodium falciparum apical membrane antigen 1 (PfAMA1) is one of the best studied (36).Expressed late in the erythrocytic replication cycle, this 83-kDa membrane protein is initially found in apical organelles called micronemes in the invasive form of the blood-stage parasite known as the merozoite (2, 18). AMA1 is subsequently processed to a 66-kDa form by removal of an N-terminal prosequence and is tr...